Abstract
Since time immemorial, placebos have been used in the treatment of patients with very different diseases. Interest in these substances has recently been renewed, since the use of placebo-controlled clinical trials has become the most useful tool to demonstrate the efficacy of a particular drug in patients with specific diseases. In inflammatory bowel disease (IBD), both in Crohn's disease and in ulcerative colitis, highly significant results have been obtained in patients in the placebo arm of clinical trials, surpassing even those achieved with drugs in other studies. Patients with IBD show certain characteristics that make them especially susceptible to the placebo effect: IBD are chronic diseases occurring in flares and pain is one of the main symptoms. In future, the placebo effect should be adequately quantified in the distinct clinical scenarios of IBD in order to design clinical trials that could demonstrate the true efficacy of the treatments investigated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
